Edition:
United States

CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

3.35USD
11 Dec 2017
Change (% chg)

$-0.11 (-3.18%)
Prev Close
$3.46
Open
$3.49
Day's High
$3.57
Day's Low
$3.30
Volume
57,876
Avg. Vol
148,144
52-wk High
$4.83
52-wk Low
$0.91

Chart for

About

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $217.97
Shares Outstanding(Mil.): 65.07
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Casi pharmaceuticals Q3 loss per share $0.03

* Casi Pharmaceuticals reports third quarter 2017 financial results

Nov 14 2017

BRIEF-CASI PHARMACEUTICALS ANNOUNCES $23.8 MLN REGISTERED DIRECT OFFERING

* CASI PHARMACEUTICALS ANNOUNCES $23.8 MILLION REGISTERED DIRECT OFFERING LED BY EXISTING SHAREHOLDERS

Oct 13 2017

BRIEF-CASI provides pipeline development update

* CASI Pharmaceuticals Inc- CFDA has granted priority review for co's import drug registration clinical trial application for EVOMELA for injection Source text for Eikon: Further company coverage:

Sep 07 2017

BRIEF-Casi Pharmaceuticals reports Q2 loss per share $0.04

* Casi Pharmaceuticals reports second quarter 2017 financial results

Aug 14 2017

Competitors

Earnings vs. Estimates